Non-Small-Cell Lung Cancer Treatment

Cytotoxic Chemotherapy, Molecular Targeted Therapy, and Immunotherapy

Abstract

Advanced non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths globally. Systemic chemotherapy using a platinum-based regimen improves overall survival of patients with advanced NSCLC. Furthermore, activating EGFR mutations and ALK fusions were identified, and these gene alterations are associated with favorable response to the tyrosine kinase inhibitors. Recently, many interests are focused on the immunotherapy for NSCLC patients. Herein, we describe cytotoxic chemotherapy, molecular targeted therapy, and immunotherapy for patients with advanced NSCLC.